Orange Book product · Generic (ANDA)
APREPITANT
APREPITANT
Generic (ANDA)ANDA 211835TE ABRX TORRENT
At a glance
Oct 21, 2020
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 21, 2020
5 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
APREPITANT
Strength
40MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 211835
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of APREPITANT
- 2022APONVIEBrand (NDA)
NDA 216457 · HERON THERAPS INC
- 2017CINVANTIBrand (NDA)
NDA 209296 · HERON THERAPS INC
- 2015EMENDBrand (NDA)
NDA 207865 · MSD MERCK CO
- 2006EMENDBrand (NDA)
NDA 021549 · MSD
- 2026APREPITANTGeneric (ANDA)
ANDA 218851 · MYLAN
- 2017APREPITANTGeneric (ANDA)
ANDA 207777 · GLENMARK SPECLT
- 2012APREPITANTGeneric (ANDA)
ANDA 090999 · SANDOZ
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
